Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2020 May 5;19(7):1530–1538. doi: 10.1158/1535-7163.MCT-19-1020

Figure 3. Cytotoxicity of BMS-P5.

Figure 3.

(A) Structure of BMS-P5, a selective PAD4 inhibitor. (B,C) Neutrophils isolated from the BM of 3 individual mice were cultured for 6h with or without 1 μM BMS-P5. Neutrophil viability (B) and apoptosis (C) were determined. (D) Indicated mouse myeloma cells were treated with BMS-P5 for 24h followed by detection of apoptosis. Mean and SD values are shown.